-->

Company Registry

QState Biosciences (AKA:Q-State~Q-State Biosciences~QuellTX)
Profile last edited on: 5/20/2020

Transformative treatments for patients with devastating genetic disorders.
Year Founded
2013
First SBIR Year
2019
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

179 Sidney Street
Cambridge, MA 02139
   (617) 945-5433
   info@qstatebio.com
   www.statebio.com
Multiple Locations:   
Congressional District:   07
County:   Middlesex

Public Profile

With PI and recipent firm for received SBIR Award called QuellTX, Q-State Biosciences is the renamed(?) small firm at that location. The firm is quite substantial in size functioning as a precision medicine company organized around care of patients having devastating genetic disorders. Q-State applies a proprietary end-to-end platform to diagnose the root cause of disease and to discover genetically targeted therapies. The frim has developed an all-optical electrophysiology platform for controlling and recording activity in electrically active cells: primary and human iPSC-derived cardiomyocytes and neurons. Combining proprietary ultrasensitive optogenetic actuators, genetically encoded voltage indicators, stem cell technology and advanced optical imaging, Q-State Biosciences uses custom instrumentation and software to probe cellular physiology with sub-micron spatial resolution and sub-millisecond temporal resolution. The firm probes dynamic cellular physiology with far higher throughput and information content than are achieved with manual patch clamp, multi electrode arrays, or calcium- or voltage-sensitive dyes. Cpincient withthe firm's Series A financing in 2018, QState merged with PAirnomix and the former head of thelatter tookk onthe CEO position with QState.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $1,123,505
A Phenotypic Screen for Osteoarthritic Pain Therapeutics Using All-Optical Electrophysiology

Key People / Management

  Matthew Fox -- Chief Executive Officer

  Mette Smedegaard Andersen -- Head of Strategy and Partnerships

  Adam Cohen -- Founder

  Kevin Coveney -- Chief Financial Officer

  Graham Dempsey -- Head of Research and Development

  Amy Elder -- Head of Chemistry

  David Gerber -- Head of Scientific Affairs

  Denise Johnson -- Head of Human Resources

  Michael Lacascia -- General Councel

  Pin Liu --

  Owen Mcmanus -- Chief Technology Officer

  Wendell Taylor -- Head of Business Development

  Kit Werley -- Head Of Engineering Researchkit Werley Head Of Engineering Research

  Eric White -- Head of Genomic Assay Development

  Erika Whyte -- Director of Lab Operations

  Luis Williams -- Head of Cell Biology